期刊
EBIOMEDICINE
卷 63, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2020.103207
关键词
Cardiovascular disease; Autophagy; Lysosome; Post-translational modification; Drug development
资金
- National Institutes of Health [R01HL138094, R01HL145176, R01HL068878, R01HL137214, R01HL134569]
- American Heart Association [17PRE33400179]
TFEB, a member of the MITF family, has been shown to regulate homeostasis in the cardiovascular system and have beneficial effects on cardiovascular diseases, making it a promising molecular target for treatment.
Cardiovascular diseases (CVDs) are the leading cause of death and a major cause of disability globally. Transcription factor EB (TFEB), as a member of the microphthalmia transcription factor (MITF) family, has been demonstrated to be a master regulator of autophagy and lysosomal biogenesis. Emerging studies suggest that TFEB regulates homeostasis in the cardiovascular system and shows beneficial effects on CVDs, including atherosclerosis, aortic aneurysm, postischemic angiogenesis, and cardiotoxicity, constituting a promising molecular target for the prevention and treatment of these diseases. Post-translational modifications regulate TFEB nuclear translocation and its transcriptional activity. Therapeutic strategies have been pursued to enhance TFEB activity and facilitate TFEB beneficial effects on CVDs. The elucidation of TFEB function and the precise underlying mechanisms will accelerate drug development and potential applications of TFEB drugs in the treatment of human diseases. (C) 2020 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据